ABILITY-3 shows higher rates of maintenance remission with adalimumab
In patients with active non-radiographic axial spondyloarthritis who achieved sustained remission with adalimumab, continued treatment with adalimumab was associated with significantly fewer patients flaring compared with treatment withdrawal. These findings from the ABILITY-3 trial were published online June 28, 2018 in The Lancet.
To continue reading this article
Continue reading your article with a eMediNexus account.